These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 29533303)

  • 1. Brief Report: Changes in Plasma RANKL-Osteoprotegerin in a Prospective, Randomized Clinical Trial of Initial Antiviral Therapy: A5260s.
    Kelesidis T; Moser CB; Johnston E; Stein JH; Dube MP; Yang OO; McComsey GA; Currier JS; Brown TT
    J Acquir Immune Defic Syndr; 2018 Jul; 78(3):362-366. PubMed ID: 29533303
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Perturbations of circulating levels of RANKL-osteoprotegerin axis in relation to lipids and progression of atherosclerosis in HIV-infected and -uninfected adults: ACTG NWCS 332/A5078 Study.
    Kelesidis T; Kendall MA; Yang OO; Hodis H; Currier JS
    AIDS Res Hum Retroviruses; 2013 Jun; 29(6):938-48. PubMed ID: 23351153
    [TBL] [Abstract][Full Text] [Related]  

  • 3. T-cell receptor activator of nuclear factor-κB ligand/osteoprotegerin imbalance is associated with HIV-induced bone loss in patients with higher CD4+ T-cell counts.
    Titanji K; Vunnava A; Foster A; Sheth AN; Lennox JL; Knezevic A; Shenvi N; Easley KA; Ofotokun I; Weitzmann MN
    AIDS; 2018 Apr; 32(7):885-894. PubMed ID: 29424771
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Osteoprotegerin and RANKL in the pathogenesis of rheumatoid arthritis-induced osteoporosis.
    Xu S; Wang Y; Lu J; Xu J
    Rheumatol Int; 2012 Nov; 32(11):3397-403. PubMed ID: 22057136
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The sex-specific association of serum osteoprotegerin and receptor activator of nuclear factor kappaB legend with bone mineral density in older adults: the Rancho Bernardo study.
    Stern A; Laughlin GA; Bergstrom J; Barrett-Connor E
    Eur J Endocrinol; 2007 May; 156(5):555-62. PubMed ID: 17468191
    [TBL] [Abstract][Full Text] [Related]  

  • 6. RANKL/OPG/TRAIL plasma levels and bone mass loss evaluation in antiretroviral naive HIV-1-positive men.
    Gibellini D; Borderi M; De Crignis E; Cicola R; Vescini F; Caudarella R; Chiodo F; Re MC
    J Med Virol; 2007 Oct; 79(10):1446-54. PubMed ID: 17705184
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of recent spinal cord injury on the OPG/RANKL system and its relationship with bone loss and the response to denosumab therapy.
    Gifre L; Ruiz-Gaspà S; Carrasco JL; Portell E; Vidal J; Muxi A; Monegal A; Guañabens N; Peris P
    Osteoporos Int; 2017 Sep; 28(9):2707-2715. PubMed ID: 28580511
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dysregulated B cell expression of RANKL and OPG correlates with loss of bone mineral density in HIV infection.
    Titanji K; Vunnava A; Sheth AN; Delille C; Lennox JL; Sanford SE; Foster A; Knezevic A; Easley KA; Weitzmann MN; Ofotokun I
    PLoS Pathog; 2014 Oct; 10(10):e1004497. PubMed ID: 25393853
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Higher levels of s-RANKL and osteoprotegerin in children and adolescents with type 1 diabetes mellitus may indicate increased osteoclast signaling and predisposition to lower bone mass: a multivariate cross-sectional analysis.
    Tsentidis C; Gourgiotis D; Kossiva L; Doulgeraki A; Marmarinos A; Galli-Tsinopoulou A; Karavanaki K
    Osteoporos Int; 2016 Apr; 27(4):1631-1643. PubMed ID: 26588909
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Correlation of plasma osteoprotegerin (OPG) and receptor activator of the nuclear factor κB ligand (RANKL) levels with clinical risk factors in patients with advanced carotid atherosclerosis.
    Giaginis C; Papadopouli A; Zira A; Katsargyris A; Klonaris C; Theocharis S
    Med Sci Monit; 2012 Oct; 18(10):CR597-604. PubMed ID: 23018352
    [TBL] [Abstract][Full Text] [Related]  

  • 11. RANKL:osteoprotegerin ratio and bone mineral density in children with untreated juvenile dermatomyositis.
    Rouster-Stevens KA; Langman CB; Price HE; Seshadri R; Shore RM; Abbott K; Pachman LM
    Arthritis Rheum; 2007 Mar; 56(3):977-83. PubMed ID: 17328075
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Osteoprotegerin and osteoprotegerin/TRAIL ratio are associated with cardiovascular dysfunction and mortality among patients with renal failure.
    Kuźniewski M; Fedak D; Dumnicka P; Stępień E; Kuśnierz-Cabala B; Cwynar M; Sułowicz W
    Adv Med Sci; 2016 Sep; 61(2):269-275. PubMed ID: 27128817
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Osteoprotegerin, but Not Receptor Activator for Nuclear Factor-κB Ligand, is Associated With Subclinical Coronary Atherosclerosis in HIV-Infected Men.
    Ketlogetswe KS; McKibben R; Jacobson LP; Li X; Dobs AS; Budoff M; Witt MD; Palella FJ; Kingsley L; Margolick JB; Post WS; Brown TT
    J Acquir Immune Defic Syndr; 2015 Dec; 70(4):362-9. PubMed ID: 26090754
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Serum RANKL, osteoprotegerin (OPG) and RANKL/OPG ratio in children with systemic lupus erythematosus.
    Ali R; Hammad A; El-Nahrery E; Hamdy N; Elhawary AK; Eid R
    Lupus; 2019 Sep; 28(10):1233-1242. PubMed ID: 31403902
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Changes in plasma levels of oxidized lipoproteins and lipoprotein subfractions with atazanavir-, raltegravir-, darunavir-based initial antiviral therapy and associations with common carotid artery intima-media thickness: ACTG 5260s.
    Kelesidis T; Tran TTT; Brown TT; Moser C; Ribaudo HJ; Dube MP; Yang OO; McComsey GA; Stein JH; Currier JS
    Antivir Ther; 2017; 22(2):113-126. PubMed ID: 27661466
    [TBL] [Abstract][Full Text] [Related]  

  • 16. OPG/RANK/RANKL signaling axis in patients with type I diabetes: Associations with parathormone and vitamin D.
    Karalazou P; Ntelios D; Chatzopoulou F; Fragou A; Taousani M; Mouzaki K; Galli-Tsinopoulou A; Kouidou S; Tzimagiorgis G
    Ital J Pediatr; 2019 Dec; 45(1):161. PubMed ID: 31823791
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Bone loss in relation to serum levels of osteoprotegerin and nuclear factor-kappaB ligand: the Tromsø Study.
    Jørgensen L; Vik A; Emaus N; Brox J; Hansen JB; Mathiesen E; Vestergaard P
    Osteoporos Int; 2010 Jun; 21(6):931-8. PubMed ID: 19701599
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Osteoprotegerin and RANKL in the pathogenesis of osteoporosis in patients with thalassaemia major.
    Pietrapertosa AC; Minenna G; Colella SM; Santeramo TM; Renni R; D'Amore M
    Panminerva Med; 2009 Mar; 51(1):17-23. PubMed ID: 19352306
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Circulating levels of osteoprotegerin and receptor activator of NF-kappaB ligand in patients with chronic renal failure.
    Shaarawy M; Fathy SA; Mehany NL; Hindy OW
    Clin Chem Lab Med; 2007; 45(11):1498-503. PubMed ID: 17970704
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Study of the osteoprotegerin/receptor activator of nuclear factor-kB ligand system association with inflammation and atherosclerosis in systemic sclerosis.
    Gamal RM; Gamal WM; Ghandour AM; Abozaid HSM; Mohamed ME; Emad Y; Abdel Galeel A
    Immunol Invest; 2018 Apr; 47(3):241-250. PubMed ID: 29336616
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.